Litigation over Vioxx has been resolved by Merck, the clinical research jobs provider has announced, with millions of Canadian dollars to be paid out as a result.
Bruce Kuhlik, executive vice president and general counsel of Merck, stated a deal has been struck in order to agree on a fixed amount for the litigation.
He said: "Under the agreement, there will be an orderly, documented and objective process to examine individual claims to determine qualification."
However, it was highlighted by the clinical jobs provider that this resolution is only applicable to legal cases in Canada and does not have any impact on ongoing litigation in other nations.
Earlier in the month, Merck revealed it has won the approval of the US Food and Drug Administration for its HIV treatment Isentress (raltegravir), which Hedy Teppler, senior director of clinical research at Merck, explained is the latest step in the firm's 25-year fight against the condition.